Setback For Autism Pioneer Seaside
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase II study testing arbaclofen in patients with idiopathic autism showed no difference from placebo on a measure of social withdrawal but demonstrated significant improvement on disease severity and social function. That’s a hint the drug may yet be the first to affect the course of the disease and not just its symptoms – if a trial can be designed to test the right endpoint.